A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors-Reference-Cited by-同舟云学术

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Published:2019-04-16 Issue:4 Volume:37 Page:738-747
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Sharman Jeffrey P.,Wheler Jennifer J.,Einhorn Lawrence,Dowlati Afshin,Shapiro Geoffrey I.,Hilton John,Burke John M.,Siddiqi Tanya,Whiting Nancy,Jalal Shadia I.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00768-6.pdf

Reference33 articles.

1. Buchan SL, Al-Shamkhani A (2012) Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-kappaB signaling. PLoS One 7(9):e45244. https://doi.org/10.1371/journal.pone.0045244

2. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG (1994) Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83(8):2045–2056

3. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85(1):1–14

4. Foyil KV, Bartlett NL (2010) Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 5(3):140–147. https://doi.org/10.1007/s11899-010-0053-y

5. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law C-L, Wahl AF (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281(15):10540–10547. https://doi.org/10.1074/jbc.M510026200

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus;Archives of Pathology & Laboratory Medicine;2022-04-26

3. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering;Communications Biology;2022-03-14

4. Methyl Donors Reduce Cell Proliferation by Diminishing Erk-Signaling and NFkB Levels, While Increasing E-Cadherin Expression in Panc-1 Cell Line;International Journal of Molecular Sciences;2022-02-25

5. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report;Frontiers in Immunology;2022-01-14